30 January 2019 - This week, key committees in the House and Senate each held hearings on the rising cost of prescription drugs. In both cases, pharmaceutical CEOs were invited, but declined to testify.

This issue has been building for months and it appears that there is mutual and bipartisan interest in addressing it during the current Congress.

For a private-sector company CEO, testifying before Congress is never enjoyable. But it is a CEO’s responsibility to provide on-the-record answers to tough questions so our representatives can be informed on public policy issues.

In the case of the Senate Finance Committee hearing, none of the pharmaceutical companies appeared and two of the CEOs said they would meet only with Chairman Chuck Grassley, Iowa Republican, in private.

Read Washington Times article